Companies /Healthcare
AbCellera Biologics Inc
NASDAQ: ABCL Biotechnology
$12.55
▲ $0.53 (+4.37%) today
Markets closed · 11:42pm ET

AbCellera Biologics (ABCL) Q2 2025 Earnings

Reported Aug 7, 2025, 4:27pm ET · SEC source
$-0.12
Beat +25.00%
EPS · est. $-0.16
$17.1M
Beat +173.69%
Revenue · est. $6.2M
−1.7%
Trailing market
ABCL vs S&P since report
1 quarter
Consecutive EPS misses

How Did ABCL Stock React to Q2 2025 Earnings?

% change · around the report
−8%0+8%+16%Aug 7Aug 8report 4:27pm ETearnings+0.9%−3.6%
−8%0+8%+16%Aug 7Aug 8earnings+0.9%−3.6%
ABCL −3.6%S&P 500 +0.9%
−8%0+8%+16%Aug 7Aug 8report 4:27pm ETearnings+1.1%−3.6%
−8%0+8%+16%Aug 7Aug 8earnings+1.1%−3.6%
ABCL −3.6%NASDAQ +1.1%
−16%−8%0+8%Aug 6Aug 15report 4:27pm ETearnings+1.6%−1.9%
−16%−8%0+8%Aug 6Aug 15earnings+1.6%−1.9%
ABCL −1.9%S&P 500 +1.6%
−16%−8%0+8%Aug 6Aug 15report 4:27pm ETearnings+1.3%−1.9%
−16%−8%0+8%Aug 6Aug 15earnings+1.3%−1.9%
ABCL −1.9%NASDAQ +1.3%
+0.24%
Day of report
+5.88%
Next session
+8.00%
One week
+0.71%
30 days

S&P 500 over the same 30 days: +2.36%.

Did ABCL Beat Earnings? Q2 2025 Results

Yes. AbCellera Biologics reported Q2 2025 earnings of $-0.12 a share on Aug 7, 2025, beating the $-0.16 consensus estimate by 25.0%. Revenue was $17.1M against a $6.2M estimate.

AbCellera Biologics delivered a standout second quarter, posting revenue of $17.08 million, a 133.3% year-over-year jump that cleared the $6.24 million consensus estimate by 173.69%, while its loss per share of $0.12 came in well ahead of the $0.16 analysts had expected, representing a 25.00% beat. The primary engine behind the revenue acceleration was a dramatic expansion in licensing revenue, which climbed to $10.45 million from just $370,000 a year ago, signaling that partner programs are beginning to generate meaningful downstream returns. Net loss narrowed modestly to $34.73 million as total operating expenses fell to $66.67 million from $100.78 million, aided in part by sharply lower depreciation and impairment charges. Beyond the financials, the quarter marked a genuine operational shift, with AbCellera initiating dosing in a Phase 1 trial of ABCL635 for vasomotor symptoms and launching a second trial for ABCL575 in atopic dermatitis. The company enters the back half of 2025 with roughly $753 million in total available liquidity, and expects initial clinical data from ABCL635 in mid-2026.

Key Takeaways
  • Licensing revenue increased significantly to $10.4 million from $0.4 million in Q2 2024
  • Research fees grew to $6.6 million from $5.5 million year-over-year
  • R&D expenses decreased to $39.2 million from $40.9 million reflecting ongoing optimization
  • G&A expenses declined to $19.0 million from $20.2 million
  • Depreciation, amortization, and impairment charges dropped significantly to $5.5 million from $36.5 million

“In the second quarter we hit two critical milestones, receiving authorization to initiate Phase 1 studies for both ABCL635 and ABCL575. I am pleased to announce today that we have successfully begun dosing the first participants in the Phase 1 study of ABCL635. This is a landmark achievement for AbCellera, one that completes our transition to a clinical-stage biotechnology company.”

AbCellera Biologics CEO, on the earnings call

What Was AbCellera Biologics's Outlook in Q2 2025?

AbCellera expects initial safety and efficacy data from the Phase 1 study of ABCL635 to be presented in mid-2026. The company has completed its platform investments in the first half of 2025 and has initiated activities at a new clinical manufacturing facility. With approximately $753 million in total available liquidity (including ~$580 million in cash, equivalents, and marketable securities plus ~$173 million in non-dilutive government funding), the company states it is well-positioned to execute on its strategy of advancing its internal pipeline and maintaining partner programs.

ABCL YoY Financials

Q2 2025 vs Q2 2024 · SEC filings Q2 2024 Q2 2025
$-40,000,000$-20,000,000$0$7.3M$17.1MRevenue$-33,745,066$-49,585,000Operating Income$-32,770,595$-34,727,000Net Income
$-40,000,000$-20,000,000$0RevenueOperating IncomeNet Income
ABCL income statement, Q2 2025 versus Q2 2024
Metric Q2 2025 Q2 2024 Year over year
Revenue $17.1M $7.3M +133.3%
Operating Income −$49.6M −$33.7M +46.9%
Net Income −$34.7M −$32.8M +6.0%

ABCL Revenue by Segment

Licensing and Royalty Revenue
Research Fees$6.6M
Licensing Revenue$10.4M

Figures from SEC filings and company reports. Not investment advice.